Overview

Biocon Biologics, headquartered in Bengaluru, India, is a unique, fully integrated leading global biosimilars player with established capabilities in the development, manufacturing and commercialization of high-quality biosimilars.

With a unique portfolio of monoclonal antibodies, insulins and conjugated recombinant proteins for diabetes, cancer, autoimmune diseases, serious eye conditions and bone health, Biocon Biologics is fully committed to the long-term sustainability of global biosimilars access.

We have demonstrated success with a proven track record of multiple successful biosimilar approvals in the U.S., Europe and several other advanced and emerging market countries. Biocon Biologics has many firsts to its credit, including the industry’s first approval of an interchangeable biosimilar, for Insulin Glargine in the U.S. We are also the first globally to receive approvals for biosimilar Trastuzumab and biosimilar Pegfilgrastim from the U.S. Food and Drug Administration (FDA).

Our 20 ‘in-market’ and ‘in-development’ biosimilars can potentially address a USD 70 billion[1] global market opportunity by FY27. Of these, eight[2] biosimilars have been commercialized in global markets and are making a difference to the lives of over 5.5 million patients annually.

A frontrunner in the global biosimilars industry, Biocon Biologics has over the past two decades invested over USD 1 billion in building dedicated ‘lab to market’ capabilities for biosimilars. This has led to the creation of state-of-the-art R&D facilities in India and large scale, globally compliant manufacturing infrastructure in India and Malaysia. We have also invested in high-end quality processes and technology to meet global quality standards and achieve regulatory compliance, in India as well as internationally. To take our biosimilars to patients we have expanded our commercial footprint to over 100 countries through a combination of direct presence, strategic partnerships and distributor tie-ups.

To strengthen its leadership position in the global biosimilars industry, Biocon Biologics has acquired the global biosimilars business of our long-term partner Viatris for over USD 3 billion in cash and stock. This is a historic milestone in our value creation journey and brings us closer to patients, customers, and payors in several advanced and emerging market countries.

Besides a robust biosimilars franchise, Biocon Biologics also has a strategic alliance with Serum Institute Life Sciences for vaccines (subject to regulatory approvals and closure of the transaction) to address the inequitable access to lifesaving vaccines worldwide.